Welcome to our dedicated page for BOSTON SCIENTIFIC SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BOSTON SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BOSTON SCIENTIFIC's regulatory disclosures and financial reporting.
Boston Scientific Corporation (BSX) reports a material cybersecurity incident that caused a global disruption of its information technology systems, temporarily affecting manufacturing and the processing and shipment of customer orders. The company has substantially restored its distribution network, resumed sterilization operations, and restarted manufacturing at most facilities worldwide.
Based on current information, Boston Scientific expects the incident to have a material impact on results for the third quarter and full year 2026 and believes it is unlikely to meet its previously issued net sales growth and adjusted EPS guidance for those periods. The company plans to update its 2026 outlook on October 28, 2026, and does not currently expect a material impact on its long-term financial condition.
BOSTON SCIENTIFIC CORP (BSX) reported that EVP, Global Operations Padraig Andrew O'Connor had 1,171 restricted stock units convert into 1,171 shares of common stock on September 2, 2026. Each unit represents a commitment to issue one Boston Scientific share. Of the shares issued, 567 shares were delivered or withheld to pay the exercise price or tax liability, with the remaining shares held directly. Following the transaction, 3,516 restricted stock units remain outstanding and are scheduled to be settled in four equal annual installments beginning on September 2, 2026. No Rule 10b5-1 trading plan is reported.
BOSTON SCIENTIFIC CORP (BSX) director Susan E. Morano reported purchasing 2,040 shares of common stock on 2026-08-25 in an open-market or private transaction at $49.2195 per share. Following this buy, she directly holds 13,784 shares of Boston Scientific common stock. The Rule 10b5-1 trading plan checkbox was not marked for this transaction.
BOSTON SCIENTIFIC CORP (BSX) reported that on August 25, 2026 it identified a cybersecurity incident affecting certain information technology systems, resulting in a global disruption to its operations. The company activated incident response protocols and engaged third-party cybersecurity experts to investigate and contain the threat.
The incident has caused, and is expected to continue to cause, disruptions and limitations of access to information systems and business applications that support operations, including the ability to process and ship customer orders. Boston Scientific is working to restore affected functions, but the timeline for full restoration is not yet known.
The company states that its investigation is ongoing and that the full scope, nature and impacts, including operational and financial effects, are not yet known. It has not yet determined whether the incident is reasonably likely to have a material impact on the company, and highlights risks such as potential litigation, reputational risk, regulatory scrutiny and possible adverse impacts on business, results of operations or financial condition.
BOSTON SCIENTIFIC CORP executive Emily Woodworth, SVP, Global Controller and CAO, reported a discretionary acquisition of 2,930 shares of common stock on 2026-08-11 at $51.19 per share. The shares were acquired indirectly through a rebalance in the company’s 401(k) Retirement Savings Plan, bringing her indirect 401(k) holdings to 2,930 shares.
A separate holding entry shows 3,123 shares held directly, which includes shares acquired under the Boston Scientific Employee Stock Purchase Plan based on the most current data available.
Boston Scientific EVP and CFO Jonathan Monson reported an indirect acquisition of 9,908 shares of Boston Scientific common stock on 2026-08-10 at $50.46 per share. The footnote states this was a discretionary rebalancing election under the company’s 401(k) Retirement Savings Plan, treated as a discretionary transaction under Rule 16b-3(f). After this transaction, he indirectly holds 9,908 shares through the 401(k) and separately reports 39,063 shares held directly.
Boston Scientific director David C. Habiger purchased 2,100 shares of common stock on August 5, 2026 in an open-market transaction at a weighted average price of $47.589 per share, with individual trade prices between $47.21 and $47.98. Following this purchase, he directly owns 17,160 shares.
FMR LLC and Abigail P. Johnson report beneficial ownership of Boston Scientific Corp common stock on a Schedule 13G/A. FMR LLC reports beneficial ownership of 46,378,258.61 shares, representing 3.1% of the outstanding common stock, as of June 30, 2026. FMR LLC has sole voting power over 39,968,563.03 shares and sole dispositive power over 46,378,258.61 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over the same 46,378,258.61 shares, but no voting power. The filing notes that one or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the total outstanding common stock.
Boston Scientific Corp director David C. Habiger reported open-market purchases of Common Stock on two days in August 2026. He bought 1,042 shares on August 3 at a weighted average price of $48.0655 per share and 140 shares on August 4 at a weighted average price of $48.5879 per share. Each trade was executed through multiple transactions within stated price ranges, with detailed per-trade pricing available on request.
Boston Scientific CEO Michael F. Mahoney purchased 186,240 shares of common stock on August 3, 2026 at a weighted average price of $48.3323 per share, with individual trades between $47.87 and $48.47. After this open-market buy, he directly owns 1,590,024 shares and indirectly holds 22,119 shares via a 401(k) Retirement Savings Plan following a discretionary rebalancing transaction at $48.4300 per share.